Contraindicated in:
Use Cautiously in:
Derm: alopecia, dry skin, nail detachment, nail discoloration, palmar-plantar erythrodysesthesia syndrome.
EENT: blurred vision, central serous retinopathy/retinal pigment epithelial detachment, conjunctivitis, dry eyes, lacrimation.
Endo: hyperglycemia.
F and E: hypercalcemia, hyperkalemia, hyperphosphatemia, hypomagnesemia, hyponatremia, hypophosphatemia.
GI: abdominal pain, ↓albumin, constipation, diarrhea, dry mouth, ↑liver enzymes, metallic taste, nausea, stomatitis, vomiting.
GU: hematuria, ↑serum creatinine, ↓ fertility (females).
Hemat: anemia, leukopenia, neutropenia, thrombocytopenia.
MS: arthralgia, pain.
Neuro: fatigue.
Resp: dyspnea.
Misc: fever.
Drug-Drug:
Therapeutic Classification: antineoplastics
Pharmacologic Classification: kinase inhibitors, fibroblast growth factor receptor inhibitor
Absorption: Unknown.
Distribution: Widely distributed to tissues.
Protein Binding: >99%.
Metabolism/Excretion: Primarily metabolized in liver by CYP2C9 and CYP3A4 isoenzymes; the CYP2C9 isoenzyme exhibits genetic polymorphism (intermediate or poor metabolizers may have significantly ↑ erdafitinib concentrations and an ↑ risk of adverse reactions).69% excreted in feces (19% as unchanged drug), 19% in urine (13% as unchanged drug).
Half-life: 59 hr.
NDC Code*